SIMCERE PHARMA Plans to Generate HKD1.554B Net Through Top-up Placing at an 8% Discount
SIMCERE PHARMA Financial Update
- Stock Performance: SIMCERE PHARMA's stock has decreased by 6.25%, closing at HKD13.20 after a drop of HKD0.880.
- Short Selling Activity: The company has experienced significant short selling, amounting to $102.49 million, with a short selling ratio of 39.934%.
Share Placement Announcement
- Placement Details: SIMCERE PHARMA plans to issue 121 million shares, representing approximately 4.66% of its enlarged share capital, at a price of HKD12.95 per share. This price reflects an 8.03% discount compared to the previous day's closing price of HKD14.08.
- Use of Proceeds: The anticipated net proceeds from this placement are around HKD1.554 billion. About 90% of these funds will be directed towards research and development (R&D) expenses, while the remaining 10% will be allocated for working capital and other general corporate purposes to support the company's ongoing operations and long-term growth.
Trade with 70% Backtested Accuracy
Analyst Views on 02096
No data
About the author
SIMCERE PHARMA: Clinical Trials for SIM0610 Greenlit in China
Company Announcement: Simcere Pharma announced that its investigational new drug candidate, SIM0610, has received Clinical Trial Approval from the National Medical Products Administration of China.
Drug Purpose: SIM0610 is a Bispecific Antibody-Drug Conjugate (BsADC) intended for evaluation in patients with locally advanced or metastatic solid tumors.
Market Activity: The company's stock experienced a slight increase of 0.050 (+0.389%) with short selling amounting to $5.28 million and a ratio of 10.987%.
Stock Information: Note that the Hong Kong stock quote is delayed by at least 15 minutes, and the short selling data is as of December 23, 2025, at 16:25.
SIMCERE PHARMA Enters Exclusive Licensing Deal with Ipsen, Potentially Worth Up to US$1.06 Billion
Licensing Agreement: SIMCERE PHARMA's subsidiary, Jiangsu Zaiming, has signed an exclusive licensing agreement with Ipsen Pharma SAS for the global rights to develop, manufacture, and commercialize the antibody-drug conjugate SIM0613 outside of Greater China.
Financial Terms: The agreement includes potential earnings of up to US$1.06 billion for SIMCERE PHARMA, consisting of a US$45 million upfront payment and additional milestone payments, along with tiered royalties on sales contingent on successful development and regulatory approvals.
SIMCERE PHARMA's ENZESHU and ENDOSTAR Added to China's National Reimbursement Drug List
Stock Performance: SIMCERE PHARMA (02096.HK) experienced a slight decline of 0.445% with a short selling amount of $9.32 million and a ratio of 11.904%.
New Drug Inclusion: ENZESHU (Suvemcitug for injection) has been officially added to the National Basic Medical Insurance Drugs Catalogue, effective January 1, 2026.
Renewal of Drug Listing: ENDOSTAR (Recombinant Human Endostatin for Injection) has successfully completed its renewal under the National Reimbursement Drug List (NRDL).
Market Information: The stock quote for HK stocks is delayed by at least 15 minutes, with short selling data as of December 5, 2025.
<Research>BOCOMI Releases November Recommended Chinese Stocks (Table)
Stock Performance: Various stocks are listed with their current prices, short selling data, and investment ratings, indicating a mix of gains and losses across different companies.
Investment Ratings: Most stocks mentioned, including FORTUNE REIT, OMNIVISION, and Alibaba, are rated as "Buy," suggesting a positive outlook from analysts.
<Study> UBS Ratings and Target Prices for Chinese Pharmaceuticals (Table)
Stock Performance Overview: Several pharmaceutical stocks showed mixed performance, with HENGRUI PHARMA and HANSOH PHARMA experiencing gains, while CSPC PHARMA and KELUN PHARM saw slight declines.
Short Selling Data: Short selling activity was notable, particularly for CSPC PHARMA and SIMCERE PHARMA, with significant ratios indicating investor caution in these stocks.
<Research>BOCOMI: Trump's New Tariffs on Imported Innovative Medications Likely to Have Minimal Effect on Chinese Pharmaceutical Companies
Tariff Announcement: US President Donald Trump will impose a 100% tariff on imported branded or patented finished drugs starting in October, unless manufacturers establish production facilities in the US; generic drugs and certain intermediates will be exempt.
Impact on Chinese Drug Companies: The tariff's effect on China's innovative drug sector is expected to be minimal, as few companies export directly to the US, with many having production capabilities in the US or using local contract manufacturers.
SIMCERE PHARMA: Clinical Trials for SIM0610 Greenlit in China
Company Announcement: Simcere Pharma announced that its investigational new drug candidate, SIM0610, has received Clinical Trial Approval from the National Medical Products Administration of China.
Drug Purpose: SIM0610 is a Bispecific Antibody-Drug Conjugate (BsADC) intended for evaluation in patients with locally advanced or metastatic solid tumors.
Market Activity: The company's stock experienced a slight increase of 0.050 (+0.389%) with short selling amounting to $5.28 million and a ratio of 10.987%.
Stock Information: Note that the Hong Kong stock quote is delayed by at least 15 minutes, and the short selling data is as of December 23, 2025, at 16:25.
SIMCERE PHARMA Enters Exclusive Licensing Deal with Ipsen, Potentially Worth Up to US$1.06 Billion
Licensing Agreement: SIMCERE PHARMA's subsidiary, Jiangsu Zaiming, has signed an exclusive licensing agreement with Ipsen Pharma SAS for the global rights to develop, manufacture, and commercialize the antibody-drug conjugate SIM0613 outside of Greater China.
Financial Terms: The agreement includes potential earnings of up to US$1.06 billion for SIMCERE PHARMA, consisting of a US$45 million upfront payment and additional milestone payments, along with tiered royalties on sales contingent on successful development and regulatory approvals.
SIMCERE PHARMA's ENZESHU and ENDOSTAR Added to China's National Reimbursement Drug List
Stock Performance: SIMCERE PHARMA (02096.HK) experienced a slight decline of 0.445% with a short selling amount of $9.32 million and a ratio of 11.904%.
New Drug Inclusion: ENZESHU (Suvemcitug for injection) has been officially added to the National Basic Medical Insurance Drugs Catalogue, effective January 1, 2026.
Renewal of Drug Listing: ENDOSTAR (Recombinant Human Endostatin for Injection) has successfully completed its renewal under the National Reimbursement Drug List (NRDL).
Market Information: The stock quote for HK stocks is delayed by at least 15 minutes, with short selling data as of December 5, 2025.
<Research>BOCOMI Releases November Recommended Chinese Stocks (Table)
Stock Performance: Various stocks are listed with their current prices, short selling data, and investment ratings, indicating a mix of gains and losses across different companies.
Investment Ratings: Most stocks mentioned, including FORTUNE REIT, OMNIVISION, and Alibaba, are rated as "Buy," suggesting a positive outlook from analysts.
<Study> UBS Ratings and Target Prices for Chinese Pharmaceuticals (Table)
Stock Performance Overview: Several pharmaceutical stocks showed mixed performance, with HENGRUI PHARMA and HANSOH PHARMA experiencing gains, while CSPC PHARMA and KELUN PHARM saw slight declines.
Short Selling Data: Short selling activity was notable, particularly for CSPC PHARMA and SIMCERE PHARMA, with significant ratios indicating investor caution in these stocks.
<Research>BOCOMI: Trump's New Tariffs on Imported Innovative Medications Likely to Have Minimal Effect on Chinese Pharmaceutical Companies
Tariff Announcement: US President Donald Trump will impose a 100% tariff on imported branded or patented finished drugs starting in October, unless manufacturers establish production facilities in the US; generic drugs and certain intermediates will be exempt.
Impact on Chinese Drug Companies: The tariff's effect on China's innovative drug sector is expected to be minimal, as few companies export directly to the US, with many having production capabilities in the US or using local contract manufacturers.
